In the current proposal we are characterizing how DNA recognition by cytosolic DNA sensors coordinates activation of both the inflammasome and type I Interferon (IRF3) activated antiviral cascades. We are proposing the cytosolic DNA sensor protein AIM2 is pivotal to activation of both cascades. Using recombinant adenovirus vector infection of macrophage cell lines or primary cells, we are determining how triggering the DNA sensing machinery signals activation of the IRF3 type I interferon response and influences maturation of these antigen presenting cells. Based on preliminary data, we show that one of the essential downstream targets of the DNA sensor response is the adaptor protein STING. The scaffolds that support DNA sensor co-activation of inflammasome/STING targets will be examined. The current proposal presents the hypothesis that AIM2 is functioning to balance the antigen-presenting cell antiviral response. We have found that AIM2 which is an interferon inducible gene is also involved in regulating type I interferon sensitivity through STAT1. We are proposing an AIM2/STAT1 regulatory loop functions to control the inflammatory/IFN sensitivity of target immune sentinel cells. The studies presented in this proposal are targeting the immune recognition response pathways that are at the heart of the innate and adaptive immune response to recombinant adenovirus vectors. We are proposing these pathways are operating in a specific manner in immune cells. The knowledge gained from these studies will contribute to enhancing vaccine, gene therapy, and anticancer therapeutic applications and they will contribute to our ability to develop new treatments for viral infections and host DNA dependent autoimmune diseases.
Immune stimulating (is) DNA directly impacts immune function in DNA vaccines, DNA dependent autoimmune diseases and antiviral Immune responses. isDNA is a new and poorly understood area of the host (antiviral) immune response. In the current proposal we are investigating the DNA sensing networks triggered by rAdV infection of murine macrophages. Our research in this exciting and important area will contribute to immune modification strategies able to enhance the potency of DNA vaccines, enhance DNA vector gene transfer, or suppress DNA induced inflammatory diseases.
|Janovitz, Tyler; Wong, Susan; Young, Neal S et al. (2017) Parvovirus B19 integration into human CD36+ erythroid progenitor cells. Virology 511:40-48|
|Huffman, Jamie B; Daniel, Gina R; Falck-Pedersen, Erik et al. (2017) The C Terminus of the Herpes Simplex Virus UL25 Protein Is Required for Release of Viral Genomes from Capsids Bound to Nuclear Pores. J Virol 91:|
|Anghelina, Daniela; Lam, Eric; Falck-Pedersen, Erik (2016) Diminished Innate Antiviral Response to Adenovirus Vectors in cGAS/STING-Deficient Mice Minimally Impacts Adaptive Immunity. J Virol 90:5915-27|
|Lam, Eric; Falck-Pedersen, Erik (2014) Unabated adenovirus replication following activation of the cGAS/STING-dependent antiviral response in human cells. J Virol 88:14426-39|
|Janovitz, Tyler; Oliveira, Thiago; Sadelain, Michel et al. (2014) Highly divergent integration profile of adeno-associated virus serotype 5 revealed by high-throughput sequencing. J Virol 88:2481-8|
|Janovitz, Tyler; Sadelain, Michel; Falck-Pedersen, Erik (2014) Adeno-associated virus type 2 preferentially integrates single genome copies with defined breakpoints. Virol J 11:15|
|Lam, Eric; Stein, Saskia; Falck-Pedersen, Erik (2014) Adenovirus detection by the cGAS/STING/TBK1 DNA sensing cascade. J Virol 88:974-81|
|Janovitz, Tyler; Klein, Isaac A; Oliveira, Thiago et al. (2013) High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration. J Virol 87:8559-68|
|Stein, Saskia C; Falck-Pedersen, Erik (2012) Sensing adenovirus infection: activation of interferon regulatory factor 3 in RAW 264.7 cells. J Virol 86:4527-37|
|Stein, Saskia C; Lam, Eric; Falck-Pedersen, Erik (2012) Cell-specific regulation of nucleic acid sensor cascades: a controlling interest in the antiviral response. J Virol 86:13303-12|